Memgen
Biotechnology, 12 Greenway PLZ, Houston, Texas, 77046, United States, 1-10 Employees
Phone Number: 83********
Who is MEMGEN
Memgen is a clinical-stage biotech company developing viral immunotherapies to harness the power of the immune system to potentially cure cancer and to protect people from infectious dise...
Read More
-
Headquarters: 12 Greenway PLZ, Houston, Texas, 77046, United States
-
Date Founded: 2004
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Memgen Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Memgen
Answer: Memgen's headquarters are located at 12 Greenway PLZ, Houston, Texas, 77046, United States
Answer: Memgen's phone number is 83********
Answer: Memgen's official website is https://memgenbio.com
Answer: Memgen's revenue is $1 Million to $5 Million
Answer: Memgen's SIC: 2834
Answer: Memgen's NAICS: 325412
Answer: Memgen has 1-10 employees
Answer: Memgen is in Biotechnology
Answer: Memgen contact info: Phone number: 83******** Website: https://memgenbio.com
Answer: Memgen is a clinical-stage biotech company developing viral immunotherapies to harness the power of the immune system to potentially cure cancer and to protect people from infectious diseases. The Companys pipeline products all utilize its proprietary CD40L transgene, MEM40, which has already demonstrated the ability to elicit powerful, antigen-specific immune responses. The Companys lead cancer immunotherapy, MEM-288, was developed in collaboration with Moffitt Cancer Center. It is an oncolytic virus engineered to selectively target cancer cells and to supercharge the immune system through expression of two unique and powerful immune modulators: MEM40 and the powerful cytokine interferon beta. MEM-288 generates a strong systemic anti-tumor immune response following intra-tumoral vaccination in multiple tumors. Memgen is close to completing the monotherapy part of a clinical trial in advanced/metastatic NSCLC. Memgen's vaccine adjuvant, MemVax, is designed to be used in combination with other vaccines to generate a strong, durable immune response. MemVax is a highly specific immune stimulant that can work with antigens across a range of delivery approaches. Memgen has over 100,000 doses of MemVax ready to go into clinical trials, and an active file with the US FDA. Memgen plans to soon begin clinical trials of MemVax in collaboration with other companies developing complementary vaccines.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month